Identification of Novel TGF-beta /Smad Gene Targets in Dermal Fibroblasts using a Combined cDNA Microarray/Promoter Transactivation Approach*

Franck VerrecchiaDagger , Mon-Li Chu§, and Alain MauvielDagger

From Dagger  INSERM U532, Hôpital Saint-Louis, 75475 Paris, France and the § Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia Pennsylvania

Received for publication, January 26, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Despite major advances in the understanding of the intimate mechanisms of transforming growth factor-beta (TGF-beta ) signaling through the Smad pathway, little progress has been made in the identification of direct target genes. In this report, using cDNA microarrays, we have focussed our attention on the characterization of extracellular matrix-related genes rapidly induced by TGF-beta in human dermal fibroblasts and attempted to identify the ones whose up-regulation by TGF-beta is Smad-mediated. For a gene to qualify as a direct Smad target, we postulated that it had to meet the following criteria: (1) rapid (30 min) and significant (at least 2-fold) elevation of steady-state mRNA levels upon TGF-beta stimulation, (2) activation of the promoter by both exogenous TGF-beta and co-transfected Smad3 expression vector, (3) up-regulation of promoter activity by TGF-beta blocked by both dominant-negative Smad3 and inhibitory Smad7 expression vectors, and (4) promoter transactivation by TGF-beta not possible in Smad3-/- mouse embryo fibroblasts. Using this stringent approach, we have identified COL1A2, COL3A1, COL6A1, COL6A3, and tissue inhibitor of metalloproteases-1 as definite TGF-beta /Smad3 targets. Extrapolation of this approach to other extracellular matrix-related gene promoters also identified COL1A1 and COL5A2, but not COL6A2, as novel Smad targets. Together, these results represent a significant step toward the identification of novel, early-induced Smad-dependent TGF-beta target genes in fibroblasts.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Members of the TGF-beta 1 superfamily (activin, bone morphogenic proteins, TGF-beta s, and decapentaplegic) are multifunctional cytokines that control various aspects of cell growth and differentiation and play an essential role in embryonic development, tissue repair, or immune homeostasis (1, 2). In addition, TGF-beta is the prototypic fibrogenic cytokine, enhancing extracellular matrix (ECM) gene expression and down-regulating that of matrix-degrading enzymes. Increased expression of TGF-beta is often associated with fibrotic states and abnormal accumulation of ECM proteins in affected tissues (3-6). The TGF-beta s signal via serine/threonine kinase transmembrane receptors, which phosphorylate cytoplasmic mediators of the Smad family (7-9). The ligand-specific Smad1, Smad2, Smad3, and Smad5 interact directly with, and are phosphorylated by, activated TGF-beta receptors type I. Smad1 and Smad5 are specific for bone morphogenic proteins, whereas Smad2 and Smad3 can be activated by both TGF-beta and activin receptors. Receptor-activated Smads are kept in the cytoplasm in the basal state bound to the protein SARA (Smad anchor for receptor activation) (10). Upon phosphorylation at their SSXS carboxyl-terminal motif, they are released from SARA and form heteromeric complexes with Smad4, a common mediator for all Smad pathways. The resulting Smad heterocomplexes are then translocated into the nucleus where they activate target genes, binding DNA either directly or in association with other transcription factors. Members of the third group of Smads, the inhibitory Smads, Smad6 and Smad7, prevent phosphorylation and/or nuclear translocation of receptor-associated Smads (7-9).

TGF-beta also initiates other signaling pathways, such as the stress-activated protein kinase/c-Jun amino-terminal kinase (JNK) pathway (11). This intracellular signaling proceeds through sequential activation of a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEKK1), a mitogen-activated protein kinase kinase (MKK4 or MKK7), and a mitogen-activated protein kinase, JNK. JNK then translocates into the nucleus where it phosphorylates several transcription factors including c-Jun, ATF-2, and Elk-1 (12), leading to specific transcriptional responses.

Although tremendous progress has been made over the past few years in the understanding of the molecular processes underlying TGF-beta signal propagation by the Smad cascade, thus far, relatively few genuine mammalian Smad gene targets have been identified. Specifically, at present, only about a dozen genes are known to contain Smad-responsive regions, binding Smad complexes directly or indirectly. These genes include, in order of characterization as Smad targets, type VII collagen (COL7A1) (13), plasminogen activator inhibitor-1 (14), the cyclin-dependent kinase inhibitor p21 (15), JunB (16), and more recently, COL1A2 (17), c-Jun (18), immunoglobulin germline Calpha (19), Smad7 (20), human germline IgA (21), platelet-derived growth factor-beta (22), beta 5 integrin (23), apoCIII (24), and the cyclin-dependent kinase inhibitor p15 (25). Interestingly, to date, all Smad gene targets identified downstream of TGF-beta are Smad3-, not Smad2-, dependent.

Despite the fundamental role played by TGF-beta in ECM remodeling and as a fibrogenic factor, little is known about the role of Smad signaling in ECM gene expression. In this report, we have used complementary techniques, differential hybridization of cDNA microarrays together with precise gene promoter analyses, to search for novel fibroblast Smad targets. This approach allowed us to characterize six novel Smad targets, COL1A1, COL3A1, COL5A2, COL6A1, COL6A3, and TIMP-1, and to propose an additional list of 49 immediate-early TGF-beta target genes whose activation by TGF-beta is rapid and does not require either protein neo-synthesis or JNK activity, therefore representing potential novel Smad targets.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Cell Cultures and Reagents-- Human dermal fibroblasts and Smad3-/- mouse embryo fibroblasts (26, 27), a kind gift from Drs. A. B. Roberts and C. Deng, National Cancer Institute, NIH, Bethesda, MD, were grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM glutamine, and antibiotics (100 units/ml penicillin, 50 µg/ml streptomycin-G, and 0.25 µg/ml FungizoneTM). Human recombinant TGF-beta 1 was from R & D Systems, Inc. (Minneapolis, MN). Curcumin and cycloheximide were purchased from Sigma.

Differential Hybridization of AtlasTM Human cDNA Expression Arrays-- Total RNA from control and TGF-beta -treated fibroblasts was obtained using an RNeasy kit (Qiagen) and treated with DNase I to avoid genomic DNA contamination of reverse transcription reactions. Radioactive cDNA synthesis was carried out as described in the AtlasTM cDNA expression arrays user manual (CLONTECH, San Diego, CA). Equal amounts of 33P-radiolabeled cDNAs (107 cpm) from control and TGF-beta -treated fibroblast RNA samples were hybridized in parallel to AtlasTM human cell interaction cDNA expression arrays (catalog number 7746-1; CLONTECH) for 18 h at 68 °C. The filters were then washed four times in 2× SSC and 1% SDS for 30 min at 68 °C and twice in 0.1× SSC and 0.5% SDS at 68 °C, according to the manufacturer's protocol. Membranes were then exposed to Eastman Kodak Co. phosphor screens for 3 days. Hybridization signals were quantified with a Storm 840 phosphorimager using ImageQuant software (Amersham Pharmacia Biotech) and normalized against glyceraldehyde-3-phosphate dehydrogenase mRNA levels in the same samples. Significant modulation of gene expression was set arbitrarily to 2-fold.

Plasmid Constructs-- Several ECM gene promoter/reporter gene constructs were used to examine the role played by TGF-beta and Smad3 in their transcriptional activity. The human COL1A2, COL6A1, COL6A2, COL7A1, and decorin promoter constructs have been described previously (28-32). Human COL6A3 promoter was cloned recently in our laboratory.2 Human COL1A1 (33), mouse COL3A1 (34), human COL5A2 (35), and human TIMP-1 (36) promoter constructs were kind gifts from Drs. Sergio A. Jimenez (Thomas Jefferson University, Philadelphia, PA), Benoit de Crombrugghe (M. D. Anderson Cancer Center, Houston, TX), Fransesco Ramirez (Mount Sinai Medical Center, New York, NY), and Dylan R. Edwards (University of Calgary, Calgary, Alberta, Canada). Full-length Smad3 and carboxyl-terminally truncated dominant-negative Smad3 (Smad3Delta C) expression vectors (kind gifts from Drs. Anita B. Roberts and Rober J. Lechleider, National Cancer Institute, NIH, Bethesda, MD and Rik Derynck, University of California at San Francisco, San Francisco, CA, respectively) have been described previously (37, 38). Smad7 expression vector (39) was a kind gift from Dr. Peter ten Dijke, Netherlands Kanker Instituut, Amsterdam, Netherlands.

Transient Cell Transfection and CAT Reporter Assays-- Transient cell transfections were performed with the calcium phosphate/DNA co-precipitation procedure. CAT activity was measured using [14C]chloramphenicol as substrate (40) followed by thin layer chromatography and quantitation with a phosphorimager.

    RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

Effects of TGF-beta on Fibroblast ECM-related Gene Expression Profiles as Measured by cDNA Microarray Analysis-- The technique of differential hybridization of cDNA expression arrays was used to identify differences in the expression pattern of 265 known ECM-related genes between control and TGF-beta -treated fibroblasts. Because Smad activation and nuclear translocation occurs within minutes and Smad-DNA complexes can be observed as early as 10 min after TGF-beta addition into fibroblast culture medium (13), we focused our attention on early time points, to determine which genes are activated rapidly by TGF-beta , as opposed to secondary gene activation that may involve protein/transcription factor neo-synthesis. At each of the time points tested (30, 60, 120, and 240 min), RNA was extracted from both control and TGF-beta -treated fibroblast cultures, and differential hybridization of cDNA arrays was performed. Among the 265 genes whose probe sets are represented onto the AtlasTM cell interactions cDNA arrays used in these experiments, 77 of them showed no significant hybridization signal in either control or TGF-beta -treated cultures at any of the time points tested (not shown). Among the 188 genes detected, 90 showed no or little alteration in their expression levels upon TGF-beta treatment. The remaining 98 genes, modulated by TGF-beta , were classified into clusters, based upon the temporal profile of their activation (Fig. 1). Clusters 1-3 contain 58 genes whose expression is strongly up-regulated 30 min after TGF-beta addition and keeps increasing with time (cluster 1), reaches a plateau (cluster 2), or returns rapidly to basal level (cluster 3). Clusters 4-6 comprise genes whose expression is delayed; their expression is not noticeably up-regulated by TGF-beta at the 30-min time point and then follows various patterns of temporal regulation. The complete list of genes contained within these clusters is provided in Table I.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Average expression profiles for each gene cluster. Six clusters were identified showing different induction kinetics by TGF-beta . Values are the mean -fold induction by TGF-beta of all genes in each cluster.

                              
View this table:
[in this window]
[in a new window]
 
Table I
List of genes classified in clusters according to their induction kinetics by TGF-beta
90/198 expressed genes derived from cDNA microarray (AtlasTM cell interaction array, Clontech catalog number 7746-1) analysis were significantly (over 2-fold) upregulated by TGF-beta in two independent experiments. They are classified in six clusters according to the kinetics of their induction (see Fig. 1). GenBankTM accession numbers, gene names, and categories for classification are provided, as supplied by Clontech. Note that clusters 1-3 contain genes whose expression is significantly upregulated by TGF-beta after 30 min.

Because our main aim was to identify immediate-early targets of the Smad pathway, genes induced as early as 30 min post-TGF-beta addition to the cultures were further studied in experiments in which on-going protein synthesis is blocked by cycloheximide. Analysis of gene expression by differential hybridization of cDNA arrays indicated that, at the 30-min time point, a similar set of 58 genes was induced by TGF-beta in the presence or absence of cycloheximide, consistent with a transcriptional response not requiring on-going protein synthesis, such as expected from direct Smad targets. It should be noted that a broad increase in gene expression induced by cycloheximide alone was also observed (not shown), a phenomenon that has been previously described (41).

In the presence of curcumin, an inhibitor of JNK activity (42), only three genes among the 58 identified above and belonging to clusters 1-3 were not stimulated by TGF-beta after 30 min, fibronectin, perlecan, and closely related low density lipoprotein receptor (43). Interestingly, it has have been shown previously that fibronectin gene activation by TGF-beta is a JNK-dependent mechanism that does not require the Smad pathway (44), consistent with the inhibitory effect of curcumin observed in our experiments. Regarding perlecan, we have shown previously that its up-regulation by TGF-beta is mediated by transcription factor NF-1 and not by Smads (45). Inversely, we found that genes previously identified as Smad targets, plasminogen activator inhibitor-1 (14), COL1A2 (17), and beta 5 integrin (23) (see Table I and the Introduction), as well as p21 (15), the latter detected in another set of experiments using different cDNA microarrays (catalog number 7741-1; CLONTECH, not shown), also belong to these early-induced gene clusters. Together, these data provide a strong argument for the specificity of our experimental approach and its appropriateness for the characterization of early-induced TGF-beta /Smad targets.

Effects of TGF-beta and Smad3 Overexpression on ECM Promoter/CAT Reporter Gene Constructs-- We next tried to determine whether the rapid elevation of steady-state mRNA levels observed for several ECM-related genes upon TGF-beta stimulation, as observed using differential cDNA array hybridization, resulted from transcriptional activation at the level of their promoter regions. We focused our attention on the 5' regulatory regions of COL1A2, COL3A1, COL6A1, COL6A3, and TIMP-1 genes, which all belong to clusters 1 and 2, corresponding to genes whose expression is enhanced at least two times by TGF-beta within 30 min. In a first set of experiments, TGF-beta responsiveness was examined. All promoter constructs tested responded to exogenous addition of TGF-beta by a 3-5-fold elevation of their activity (Fig. 2A). As a first approach to determine whether these promoters were sensitive to Smad activation downstream of TGF-beta , co-transfection experiments were performed in which each ECM promoter/CAT reporter construct was co-transfected with a Smad3 expression vector. As shown in Fig. 2B, Smad3 overexpression led to significant up-regulation of each of the promoters tested, indicating that the Smad pathway may be involved in the TGF-beta effect.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Exogenous TGF-beta and Smad3 overexpression transactivate the COL1A2, COL3A1, COL6A1, COL6A3, and TIMP-1 promoters. A, human dermal fibroblast cultures were transfected with COL1A1, COL3A1, COL6A1, COL6A3, or TIMP-1 promoter/CAT reporter constructs. 3 h later, TGF-beta (10 ng/ml) was added to the medium, and the incubation was continued for 24 h, at which time CAT activity was determined. B, empty pcDNA3 or Smad3 expression vectors were co-transfected with the same promoter/reporter constructs as in panel A. 24 h later CAT activity was determined. -Fold induction of promoter activities by TGF-beta (panel A) or Smad3 (panel B) is shown as the mean ± S.D. of at least three independent experiments performed in duplicate.

Dominant-Negative Smad3 and Inhibitory Smad7 Expression Block TGF-beta -induced ECM Promoter Activation-- If the Smad cascade is responsible for the up-regulation of a given gene by TGF-beta , then the expression of either a dominant-negative Smad3 or inhibitory Smad7 should block its activation by TGF-beta . To test this hypothesis, all promoter constructs shown above to respond to both TGF-beta and Smad3 overexpression (see Fig. 2) were co-transfected with either Smad3Delta C or Smad7 expression vector. In both cases up-regulation of promoter activity by TGF-beta was blocked (Fig. 3), suggesting that the COL1A2, COL3A1, COL6A1, COL6A3, and TIMP-1 genes are immediate-early targets of the TGF-beta /Smad3/4 signaling cascade. It may be extrapolated, although it remains to be investigated precisely, that most genes identified in clusters 1-3 whose mRNA steady-state levels were elevated at least two times by TGF-beta after 30 min, but whose 5'-end regulatory regions were not analyzed functionally for Smad responsiveness, also represent direct Smad targets.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Overexpression of dominant-negative Smad3 or Smad7 prevents COL1A2, COL3A1, COL6A1, COL6A3, and TIMP-1 promoter up-regulation by TGF-beta . Human dermal fibroblast cultures were co-transfected with COL1A1, COL3A1, COL6A1, COL6A3, or TIMP-1 promoter/CAT reporter constructs, together with empty pcDNA3, Smad3Delta C, or Smad7 expression vectors, as indicated. 3 h later, TGF-beta (10 ng/ml) was added (+) or not (-) to the medium, and incubations were continued for 24 h before CAT activity was determined. Relative promoter activities (mean ± S.D.) of at least three independent experiments performed in duplicate are shown in the form of bar graphs.

COL1A1 and COL5A2, but Not COL6A2, Are Direct Smad Targets-- Because both COL6A1 and COL6A3 were characterized as direct Smad targets (see above), we wanted to determine whether COL6A2, which encodes the alpha (2) chain of heterotrimeric type VI collagen, was similarly up-regulated by TGF-beta . Interestingly, when a 2.5-kilobase pair COL6A2 promoter fragment (24) was tested in an identical experimental system, we observed that it did not confer either TGF-beta or Smad3 responsiveness (not shown), suggesting a differential regulation of the three genes encoding type VI collagen by TGF-beta , where both COL6A1 and COL6A3 are coordinately regulated and are direct Smad targets, whereas COL6A2 is not. These data differ slightly from previous observations indicating specific up-regulation of COL6A3 but not COL6A1 or COL6A2 by TGF-beta , when mRNA steady-state levels were detected after 48 h of stimulation (46).

mRNA steady-state levels of COL1A1, which encodes the alpha (1) chain of type I collagen, have been shown previously to be elevated by TGF-beta (47). The corresponding promoter was found to be up-regulated by both exogenous addition of TGF-beta and co-transfection of a Smad3 expression vector (not shown). In addition, its activation by TGF-beta was blocked by both dominant-negative Smad3 and Smad7 overexpression (not shown), indicating that the COL1A1 promoter is also a Smad target. Interestingly, these data corroborate the previously described coordinate regulation of COL1A1 and COL1A2 (48-50) and indicate transcriptional coordination by TGF-beta , orchestrated by Smad-dependent mechanisms. Identical results were obtained with the alpha (2) type V collagen gene (COL5A2) promoter, indicating that the latter is also a direct Smad target (not shown).

Absence of COL1A1, COL1A2, COL3A1, COL5A2, COL6A1, COL6A3, and TIMP-1 Promoter Transactivation by TGF-beta in Smad3-/- Mouse Embryo Fibroblasts-- To ascertain the role played by Smad3 in the transactivation of the ECM-related promoters identified above, transient cell transfection experiments were carried out using either wild-type or Smad3-/- mouse embryo fibroblasts (26, 27). As expected from the data presented above in which either dominant-negative Smad3 or inhibitory Smad7 expression vectors blocked TGF-beta effect, no TGF-beta -driven transactivation of the COL1A1, COL1A2, COL3A1, COL5A2, COL6A1, COL6A3, and TIMP-1 promoters was observed in Smad3-/- mouse embryo fibroblasts. On the other hand, all promoters add their activity significantly increased by TGF-beta in the corresponding wild-type mouse embryo fibroblasts (not shown). These results confirm the role played by Smad3 to mediate TGF-beta transactivation of these ECM promoters.

The implication of TGF-beta in fibrotic processes has long been suspected (3-6). The demonstration that several genes encoding fibrillar collagens, COL1A1, COL1A2, COL3A1, and COL5A2, are up-regulated by TGF-beta acting directly through the Smad pathway indicates that the latter is likely to play a key role in the development of tissue fibrosis. It also suggests that therapeutic approaches directed toward the Smad cascade may prove useful in the treatment of fibrotic disorders.

In conclusion, using cell matrix interaction-specific commercial cDNA microarrays we have identified 58 immediate-early targets for TGF-beta . Only three of these 58 genes had their activation blocked by curcumin, a selective inhibitor of JNK, a signaling pathway alternative to the Smad cascade downstream of the TGF-beta receptors. These data suggest that the JNK pathway downstream of the TGF-beta receptors likely affects very few early ECM-related target genes as compared with the Smad pathway. Using promoter/reporter gene constructs to analyze the transcriptional responsiveness to the TGF-beta /Smad pathway of several genes identified by differential hybridization of cDNA arrays, we have formally identified six novel TGF-beta /Smad immediate-early gene targets, namely COL1A1, COL3A1, COL5A2, COL6A1, COL6A3, and TIMP-1. Together with the identification of 49 other immediate-early TGF-beta gene targets, this study represents a major leap forward in the identification of TGF-beta /Smad targets.

    ACKNOWLEDGEMENTS

Charlotte Tacheau provided excellent technical help.

    FOOTNOTES

* This work was supported by grants from the Association pour la Recherche contre le Cancer (France; Subvention Libre 9058), INSERM, France (APEX 4X809D), and Electricité de France (Service de Radioprotection) (to A. M.) and by National Institutes of Health Grant AR38912 (to M. L. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: INSERM U532, Institut de Recherche sur la Peau, Pavillon Bazin, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75475 Paris, Cedex 10, France. Tel.: 33 1 53 72 20 69; Fax: 33 1 53 72 20 51; E-mail: mauviel@chu-stlouis.fr.

Published, JBC Papers in Press, March 8, 2001, DOI 10.1074/jbc.M100754200

2 R. Z. Zhang and M.-L. Chu, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: TGF-beta (s), transforming growth factor-beta (s); CAT, chloramphenicol acetyltransferase; ECM, extracellular matrix; JNK, Jun amino-terminal kinase; TIMP, tissue inhibitor of metalloproteases.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
REFERENCES

1. Letterio, J. J., and Roberts, A. B. (1997) Clin. Immunol. Immunopathol. 84, 244-250[CrossRef][Medline] [Order article via Infotrieve]
2. Massagué, J. (1998) Annu. Rev. Biochem. 67, 753-791[CrossRef][Medline] [Order article via Infotrieve]
3. Khalil, N., and Greenberg, A. H. (1991) Ciba Found. Symp. 157, 194-207[Medline] [Order article via Infotrieve]
4. Border, W. A., and Noble, N. A. (1997) Kidney Int. 51, 1388-1396[Medline] [Order article via Infotrieve]
5. Branton, M. H., and Kopp, J. B. (1999) Microbes Infect. 1, 1349-1365[CrossRef][Medline] [Order article via Infotrieve]
6. Martin, M., Lefaix, J., and Delanian, S. (2000) Int. J. Radiat. Oncol. Biol. Phys. 47, 277-290[CrossRef][Medline] [Order article via Infotrieve]
7. Piek, E., Heldin, C. H., and Ten Dijke, P. (1999) FASEB. J. 13, 2105-2124[Abstract/Free Full Text]
8. Massagué, J., and Wotton, D. (2000) EMBO J. 19, 1745-1754[Abstract/Free Full Text]
9. Derynck, R., Zhang, Y., and Feng, X. H. (1998) Cell 95, 737-740[Medline] [Order article via Infotrieve]
10. Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L., and Wrana, J. L. (1998) Cell 95, 779-791[Medline] [Order article via Infotrieve]
11. Atfi, A., Djelloul, S., Chastre, E., Davis, R., and Gespach, C. (1997) J. Biol. Chem. 272, 1429-1432[Abstract/Free Full Text]
12. Ip, Y. T., and Davis, R. J. (1998) Curr. Opin. Cell Biol. 10, 205-219[CrossRef][Medline] [Order article via Infotrieve]
13. Vindevoghel, L., Kon, A., Lechleider, R. J, Uitto, J., Roberts, A. B., and Mauviel, A. (1998) J. Biol. Chem. 273, 13053-13057[Abstract/Free Full Text]
14. Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier, J. M. (1998) EMBO J. 17, 3091-3100[Abstract/Free Full Text]
15. Moustakas, A., and Kardassis, D. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 6733-6738[Abstract/Free Full Text]
16. Jonk, L. J., Itoh, S., Heldin, C. H., ten Dijke, P., and Kruijer, W. (1998) J. Biol. Chem. 273, 21145-21152[Abstract/Free Full Text]
17. Chen, S. J., Yuan, W., Mori, Y., Levenson, A., Trojanowska, M., and Varga, J. (1999) J. Invest. Dermatol. 112, 49-57[Abstract/Free Full Text]
18. Wong, C., Rougier-Chapman, E. M., Frederick, J. P., Datto, M. B., Liberati, N. T., Li, J. M., and Wang, X. F. (1999) Mol. Cell. Biol. 19, 1821-1830[Abstract/Free Full Text]
19. Hanai, J., Chen, L. F., Kanno, T., Ohtani-Fujita, N., Kim, W. Y., Guo, W. H., Imamura, T., Ishidou, Y., Fukuchi, M., Shi, M. J., Stavnezer, J., Kawabata, M., Miyazono, K., and Ito, Y. (1999) J. Biol. Chem. 274, 31577-31582[Abstract/Free Full Text]
20. Nagarajan, R. P., Zhang, J., Li, W., and Chen, Y. (1999) J. Biol. Chem. 274, 33412-33418[Abstract/Free Full Text]
21. Pardali, E., Xie, X. Q., Tsapogas, P., Itoh, S., Arvanitidis, K., Heldin, C. H., ten Dijke, P., Grundstrom, T., and Sideras, P. (2000) J. Biol. Chem. 275, 3552-3560[Abstract/Free Full Text]
22. Taylor, L. M., and Khachigian, L. M. (2000) J. Biol. Chem. 275, 16709-16716[Abstract/Free Full Text]
23. Lai, C. F., Feng, X., Nishimura, R., Teitelbaum, S. L., Avioli, L. V., Ross, F. P., and Cheng, S. L. (2000) J. Biol. Chem. 275, 36400-36406[Abstract/Free Full Text]
24. Kardassis, D., Pardali, K., and Zannis, V. I. (2000) J. Biol. Chem. 275, 41405-41414[Abstract/Free Full Text]
25. Feng, X. H., Lin, X., and Derynck, R. (2000) EMBO J. 19, 5178-5193[Abstract/Free Full Text]
26. Yang, X., Letterio, J. J., Lechleider, R. J., Chen, L., Hayman, R., Gu, H., Roberts, A. B., and Deng, C. (1999) EMBO J. 18, 1280-1291[Abstract/Free Full Text]
27. Ashcroft, G. S., Yang, X., Glick, A. B., Weinstein, M., Letterio, J. L., Mizel, D. E., Anzano, M., Greenwell-Wild, T., Wahl, S. M., Deng, C., and Roberts, A. B. (1999) Nat. Cell Biol. 1, 260-266[CrossRef][Medline] [Order article via Infotrieve]
28. Mauviel, A., Santra, M., Chen, Y. Q., Uitto, J., and Iozzo, R. V. (1995) J. Biol. Chem. 270, 11692-11700[Abstract/Free Full Text]
29. Saitta, B., and Chu, M. L. (1994) Eur. J. Biochem. 223, 675-682[Abstract]
30. Saitta, B., and Chu, M. L. (1995) Eur. J. Biochem. 234, 542-549[Abstract]
31. Chung, K. Y., Agarwal, A., Uitto, J., and Mauviel, A. (1996) J. Biol. Chem. 271, 3272-3278[Abstract/Free Full Text]
32. Vindevoghel, L., Chung, K. Y., Davis, A., Kouba, D., Kivirikko, S., Alder, H., Uitto, J., and Mauviel, A. (1997) J. Biol. Chem. 272, 10196-10204[Abstract/Free Full Text]
33. Li, L., Artlett, C. M., Jimenez, S. A., Hall, D. J., and Varga, J. (1995) Gene 164, 229-234[CrossRef][Medline] [Order article via Infotrieve]
34. Mudryj, M., and de Crombrugghe, B. (1988) Nucleic Acids Res. 16, 7513-7526[Abstract]
35. Truter, S., Di Liberto, M., Inagaki, Y., and Ramirez, F. (1992) J. Biol. Chem. 267, 25389-25395[Abstract/Free Full Text]
36. Clark, I. M., Rowan, A. D., Edwards, D. R., Bech-Hansen, T., Mann, D. A., Bahr, M. J., and Cawston, T. E. (1997) Biochem. J. 324, 611-617[Medline] [Order article via Infotrieve]
37. Vindevoghel, L., Lechleider, R. J., Kon, A., de Caestecker, M. P., Uitto, J., Roberts, A. B., and Mauviel, A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14769-14774[Abstract/Free Full Text]
38. Zhang, Y., Feng, X., We, R., and Derynck, R. (1996) Nature 383, 168-172[CrossRef][Medline] [Order article via Infotrieve]
39. Nakao, A., Afrakhte, M., Moren, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N. E., Heldin, C. H., and ten Dijke, P. (1997) Nature 389, 631-635[CrossRef][Medline] [Order article via Infotrieve]
40. Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Mol. Cell. Biol. 2, 1044-1051[Medline] [Order article via Infotrieve]
41. Iyer, V. R., Eisen, M. B., Ross, D. T., Schuler, G., Moore, T., Lee, J. C. F., Trent, J. M., Staudt, L. M., Hudson, J., Jr., Boguski, M. S., Lashkari, D., Shalon, D., Botstein, D., and Brown, P. O. (1999) Science 283, 83-87[Abstract/Free Full Text]
42. Chen, Y. R., and Tan, T. H. (1998) Oncogene 17, 173-178[CrossRef][Medline] [Order article via Infotrieve]
43. Murdoch, A. D., Dodge, G. R., Cohen, I., Tuan, R. S., and Iozzo, R. V. (1992) J. Biol. Chem. 267, 8544-8557[Abstract/Free Full Text]
44. Hocevar, B. A., Brown, T. L., and Howe, P. H. (1999) EMBO J. 18, 1345-1356[Abstract/Free Full Text]
45. Iozzo, R. V., Pillarisetti, J., Sharma, B., Murdoch, A. D., Danielson, K. G., Uitto, J., and Mauviel, A. (1997) J. Biol. Chem. 272, 5219-5228[Abstract/Free Full Text]
46. Heckmann, M., Aumailley, M., Chu, M. L., Timpl, R., and Krieg, T. (1992) FEBS Lett. 310, 79-82[CrossRef][Medline] [Order article via Infotrieve]
47. Varga, J., Rosenbloom, J., and Jimenez, S. A. (1987) Biochem. J. 247, 597-604[Medline] [Order article via Infotrieve]
48. Sandmeyer, S., Gallis, B., and Bornstein, P. (1981) J. Biol. Chem. 256, 5022-5028[Abstract]
49. Cockayne, D., and Cutroneo, K. R. (1988) Biochemistry 27, 2736-2745[Medline] [Order article via Infotrieve]
50. Hata, R. (1995) Cell Biol. Int. Rep. 19, 735-741[CrossRef]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.